Anti-KAT3B / p300 antibody (ab2830)

Overview

• Product nameAnti-KAT3B / p300 antibodySee all KAT3B / p300 primary antibodies ...
• Description
  Rabbit polyclonal to KAT3B / p300
• Tested applicationsWB more details
• Species reactivity
  Reacts with: Human
  
• Immunogen

  Synthetic peptide: GTSGPNQGPTQSTC , corresponding to amino acids 139-151 in the nuclear factor binding domain of Human p300.

  Run BLAST with Run BLAST with

Properties

• FormLiquid
• Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
• Storage bufferPBS, 1 mg/ml BSA, 0.05% sodium azide
• Concentration information loading...
• PurityIgG fraction
• Clonality Polyclonal
• IsotypeIgG
• Research Areas
  • Metabolism
  • Types of disease
  • Obesity

  • Metabolism
  • Types of disease
  • Cancer

  • Metabolism
  • Pathways and Processes
  • Metabolism processes
  • Hypoxia

  • Stem Cells
  • Signaling Pathways
  • TGF beta
  • Nuclear

  • Cancer
  • Oncoproteins/suppressors
  • Tumor suppressors
  • Rb family

  • Cancer
  • Cancer Metabolism
  • Response to hypoxia

  • Epigenetics and Nuclear Signaling
  • Transcription
  • Other factors

  • Epigenetics and Nuclear Signaling
  • Chromatin Modifying Enzymes
  • Acetylation

Applications

Target

• FunctionFunctions as histone acetyltransferase and regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation. Mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. Also functions as acetyltransferase for nonhistone targets. Acetylates 'Lys-131' of ALX1 and acts as its coactivator in the presence of CREBBP. Acetylates SIRT2 and is proposed to indirectly increase the transcriptional activity of TP53 through acetylation and subsequent attenuation of SIRT2 deacetylase function. Acetylates HDAC1 leading to its inactivation and modulation of transcription. Acts as a TFAP2A-mediated transcriptional coactivator in presence of CITED2. Plays a role as a coactivator of NEUROD1-dependent transcription of the secretin and p21 genes and controls terminal differentiation of cells in the intestinal epithelium. Promotes cardiac myocyte enlargement. Can also mediate transcriptional repression. Binds to and may be involved in the transforming capacity of the adenovirus E1A protein. In case of HIV-1 infection, it is recruited by the viral protein Tat. Regulates Tat's transactivating activity and may help inducing chromatin remodeling of proviral genes. Acetylates FOXO1 and enhances its transcriptional activity.
• Involvement in diseaseNote=Defects in EP300 may play a role in epithelial cancer.
  Note=Chromosomal aberrations involving EP300 may be a cause of acute myeloid leukemias. Translocation t(8;22)(p11;q13) with KAT6A.
  Rubinstein-Taybi syndrome 2 (RSTS2) [MIM:613684]: A disorder characterized by craniofacial abnormalities, postnatal growth deficiency, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies. Some individuals with RSTS2 have less severe mental impairment, more severe microcephaly, and a greater degree of changes in facial bone structure than RSTS1 patients. Note=The disease is caused by mutations affecting the gene represented in this entry.
• Sequence similaritiesContains 1 bromo domain.
  Contains 1 KIX domain.
  Contains 2 TAZ-type zinc fingers.
  Contains 1 ZZ-type zinc finger.
• DomainThe CRD1 domain (cell cycle regulatory domain 1) mediates transcriptional repression of a subset of p300 responsive genes; it can be de-repressed by CDKN1A/p21WAF1 at least at some promoters. It conatins sumoylation and acetylation sites and the same lysine residues may be targeted for the respective modifications. It is proposed that deacetylation by SIRT1 allows sumoylation leading to suppressed activity.
• Post-translational
  modificationsAcetylated on Lys at up to 17 positions by intermolecular autocatalysis. Deacetylated in the transcriptional repression domain (CRD1) by SIRT1, preferentially at Lys-1020.
  Citrullinated at Arg-2142 by PADI4, which impairs methylation by CARM1 and promotes interaction with NCOA2/GRIP1.
  Methylated at Arg-580 and Arg-604 in the KIX domain by CARM1, which blocks association with CREB, inhibits CREB signaling and activates apoptotic response. Also methylated at Arg-2142 by CARM1, which impairs interaction with NCOA2/GRIP1.
  Sumoylated; sumoylation in the transcriptional repression domain (CRD1) mediates transcriptional repression. Desumoylated by SENP3 through the removal of SUMO2 and SUMO3.
  Probable target of ubiquitination by FBXO3, leading to rapid proteasome-dependent degradation.
  Phosphorylated by HIPK2 in a RUNX1-dependent manner. This phosphorylation that activates EP300 happens when RUNX1 is associated with DNA and CBFB. Phosphorylated by ROCK2 and this enhances its activity. Phosphorylation at Ser-89 by AMPK reduces interaction with nuclear receptors, such as PPARG.
• Cellular localizationCytoplasm. Nucleus. In the presence of ALX1 relocalizes from the cytoplasm to the nucleus. Co-localizes with ROCK2 in the nucleus.

Target information above from: UniProt accession Q09472 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 2033 Human
  • Omim: 602700 Human
  • SwissProt: Q09472 Human
  • Unigene: 517517 Human

• Alternative names
  CREBBP/EP300 inhibitory protein 1 antibodyCyclic AMP responsive enhancer binding protein antibodyE1A associated protein p300 antibody

  E1A binding protein p300 antibodyE1A-associated protein p300 antibodyEC 2.3.1.48 antibodyEP300 antibodyEP300: E1A binding protein p300 antibodyEP300_HUMAN antibodyHistone acetyltransferase p300 antibodyp300 HAT antibodyRB and P300 binding protein EID 1 antibodyRetinoblastoma protein associated protein antibodyRSTS2 antibody

  see all

Anti-KAT3B / p300 antibody images

• 

  ChIP - KAT3B / p300 antibody (ab2830)
   

  Sonicated Chromatin prepared from untreated or 17beta-estradiol (E2) treated MCF7 cells was subjected to the ChIP procedure with ab2830 to p300 and the immunoprecipitated chromatin was analysed in the proximal region of the estrogen-responsive pS2 promoter (as shown above) and quantified by real-time PCR (values are % of inputs). The primers are designed to follow the nucleosome E (including the Estrogen Responsive Element ERE). 3 µl of ab2830 and 4x106 cells were used in each ChIP experiment.

   

  Comments: 

  I think ab2830 is maybe working in ChIPs, but the amount of DNA immunoprecipitated is very weak and not really significant. However, the results make sense because you can expect an increase of the p300 recruitment during the pS2 gene activation.